Authors’ Reply to Ravi Jandhyala’s Comment on “Patient Registries: An Underused Resource for Medicines Evaluation: Operational Proposals for Increasing the Use of Patient Registries in Regulatory Assessments”

Patricia McGettigan (), Carla Alonso Olmo, Kelly Plueschke, Mireia Castillon, Daniel Zondag, Priya Bahri, Xavier Kurz and Peter G. M. Mol
Additional contact information
Patricia McGettigan: Queen Mary University of London
Carla Alonso Olmo: European Medicines Agency
Kelly Plueschke: European Medicines Agency
Mireia Castillon: European Medicines Agency
Daniel Zondag: European Medicines Agency
Priya Bahri: European Medicines Agency
Xavier Kurz: European Medicines Agency
Peter G. M. Mol: University of Groningen

Drug Safety, 2019, vol. 42, issue 12, No 12, 1517-1518

Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-019-00863-w Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:42:y:2019:i:12:d:10.1007_s40264-019-00863-w

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-019-00863-w

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().